Portal de Periódicos da CAPES

ANDROGEN DEPRIVATION THERAPY FOR ASYMPTOMATIC ADVANCED PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERA: A NATIONAL SURVEY OF UROLOGIST BELIEFS AND PRACTICES

1998; Lippincott Williams & Wilkins; Volume: 159; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(01)63223-3

1527-3792

John H. Wasson, Floyd J. Fowler, Michael J. Barry,

Hormonal and reproductive studies

No AccessJournal of UrologyClinical Urology: Original Articles1 Jun 1998ANDROGEN DEPRIVATION THERAPY FOR ASYMPTOMATIC ADVANCED PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERA: A NATIONAL SURVEY OF UROLOGIST BELIEFS AND PRACTICES JOHN H. WASSON, FLOYD J. FOWLER, and MICHAEL J. BARRY JOHN H. WASSONJOHN H. WASSON , FLOYD J. FOWLERFLOYD J. FOWLER , and MICHAEL J. BARRYMICHAEL J. BARRY View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)63223-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The use of androgen deprivation for prostate cancer without symptomatic metastases to the skeleton is controversial. However, by 1995 the use of medical androgen deprivation by injection was the thirteenth largest category of physician reimbursement by Medicare. To what degree do urologist attitudes towards androgen deprivation account for this growth? Materials and Methods: A survey was mailed to 582 United States urologists practicing at least 20 hours per week in 1995 which asked about use of androgen deprivation therapy when prostate specific antigen (PSA) levels rise after primary therapy (surgery or radiation). They were also asked whether they believed androgen deprivation provided a survival benefit for patients with asymptomatic stages C and D disease. Results: The response rate was 68%. Of the respondents 68% reported that they recommend androgen deprivation at least half of the time for men whose PSA is newly or persistently elevated following radical prostatectomy. Most (81%) urologists who believe that androgen deprivation offers a survival benefit for stage C disease said they prescribed it but more than half (53%) who do not believe in the efficacy of this treatment also said they still prescribe it. Conclusions: Many urologists maintain an inclination to prescribe androgen deprivation for a rising or elevated PSA despite the absence of information about the benefit of this approach and their own conflicting beliefs. References 1 : Hormone therapy for prostate cancer: results of the Veteran's Administration Cooperative Urological Research Group studies. NCI Monographs1988; 7: 165. Google Scholar 2 : Combined surgery and immediate adjuvant hormonal treatment for Stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Sem. Urol.1990; 8: 175. Medline, Google Scholar 3 : Prognosis of patients with Stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J. Urol.1990; 144: 700. Link, Google Scholar 4 : The value of testosterone deprivation in Stage D1 carcinoma of the prostate. J. Urol.1988; 139: 1242. Link, Google Scholar 5 : Advanced prostatic carcinoma: Early versus late endocrine therapy. Urol. Clin. N. Amer.1991; 18: 15. Crossref, Medline, Google Scholar 6 : Health-related quality of life of men undergoing different treatments for advanced prostate cancer. J. Urol.1997; 157: 333. abstract 1301. Medline, Google Scholar 7 : Estrogens in the treatment of prostate cancer. J. Urol.1995; 154: 1991. Link, Google Scholar 8 : Update of hormonal treatment in cancer of the prostate. Anticancer Drugs1993; 4: 301. Crossref, Medline, Google Scholar 9 : Hormone therapy for prostate cancer: a topical perspective. Urology1996; 47: 3. Crossref, Medline, Google Scholar 10 : Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice?. Prostate1995; 27: 233. Crossref, Medline, Google Scholar 11 : The case for early endocrine treatment of advanced or metastatic prostate cancer. Prostate1996; 28: 201. Crossref, Medline, Google Scholar 12 : Carcinoma of prostate: case against immediate hormonal therapy. Prostate1996; 28: 205. Crossref, Medline, Google Scholar 13 : Practice trends in the diagnosis and management of prostate cancer in the United States. J. Urol.1995; 154: 207. Link, Google Scholar 14 : Report on the management of clinically localized prostate cancer. In: . Baltimore: American Urological Association, Inc.1995. Google Scholar 15 : Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology1995; 46: 220. Crossref, Medline, Google Scholar 16 : Prostate cancer in the era of prostate-specific antigen. Curr. Opin. Oncol.1995; 7: 281. Crossref, Medline, Google Scholar 17 The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: the initial results of the Medical Research Council trial. Brit. Med. J.1997; 79: 235. Google Scholar 18 Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3282 deaths in 5710 patients. Lancet1995; 346: 265. Medline, Google Scholar 19 : Comparison of bilateral orchiectomy with or without flutemide for the treatment of patients with stage D2 adenocarcinoma of the prostate: results of NCI Intergroup Study 0105 (SWOG and ECOG). J. Urol.1997; 157: 336. abstract 1311. Google Scholar 20 : Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 Prostatic Carcinoma. Urology1997; 49: 65. Crossref, Medline, Google Scholar 21 Health Care Financing Administration: Medicare claims data, calendar year 1995. Google Scholar 22 : Osteopenia in men with prostate cancer treated with androgen deprivation. J. Urol.1997; 157: 232. abstract 906. Google Scholar From Dartmouth Medical School, Hanover, New Hampshire, and Center for Survey Research, University of Massachusetts-Boston and Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Hoxha I, Busato A and Luta X (2016) Medical Practice Variations in Reproductive, Obstetric, and Gynecological Care Medical Practice Variations, 10.1007/978-1-4899-7603-1_76, (141-160), . Taneja S (2015) Re: Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-Cause Mortality in Elderly Men with Prostate CancerJournal of Urology, VOL. 193, NO. 6, (1982-1983), Online publication date: 1-Jun-2015. Agarwal M and Agrawal M (2012) Can Subepididymal Orchiectomy Re-emerge as the Treatment of Choice in Patients with Advanced Prostatic Carcinoma?Indian Journal of Surgery, 10.1007/s12262-012-0741-z, VOL. 77, NO. 1, (23-27), Online publication date: 1-Feb-2015. Hoxha I, Busato A and Luta X (2015) Medical Practice Variations in Reproductive, Obstetric, and Gynaecological Care Medical Practice Variations, 10.1007/978-1-4899-7573-7_76-1, (1-21), . Shahinian V (2011) Androgen deprivation for prostate cancerCancer, 10.1002/cncr.26624, VOL. 118, NO. 13, (3232-3235), Online publication date: 1-Jul-2012. Luján S, García‐Fadrique G, Morales G, Morera J, Broseta E and Jiménez‐Cruz J (2012) Are Urology Residents Ready to Treat Premature Ejaculation After Their Training?The Journal of Sexual Medicine, 10.1111/j.1743-6109.2011.02571.x, VOL. 9, NO. 2, (404-410), Online publication date: 1-Feb-2012. Hwang T, Lin Y, Lee M, Juang G, Yeh C, Cheng Y, Chou K, Chen H and Tsai T (2010) The Effects of Medical Castration on Testes in Patients With Advanced Prostate CancerUrological Science, 10.1016/S1879-5226(10)60038-3, VOL. 21, NO. 4, (169-174), Online publication date: 1-Dec-2010. Skolarus T, Zhang Y, Miller D, Wei J and Hollenbeck B (2010) The Economic Burden of Prostate Cancer Survivorship CareJournal of Urology, VOL. 184, NO. 2, (532-538), Online publication date: 1-Aug-2010. Ahlborg H, Nguyen N, Center J, Eisman J and Nguyen T (2008) Incidence and risk factors for low trauma fractures in men with prostate cancerBone, 10.1016/j.bone.2008.05.003, VOL. 43, NO. 3, (556-560), Online publication date: 1-Sep-2008. Weight C, Klein E and Jones J (2008) Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare populationCancer, 10.1002/cncr.23421, VOL. 112, NO. 10, (2195-2201), Online publication date: 15-May-2008. Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T and Ichikawa T (2007) Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancerInternational Journal of Urology, 10.1111/j.1442-2042.2007.01748.x, VOL. 14, NO. 5, (416-421), Online publication date: 1-May-2007. Ockrim J, Lalani E and Abel P (2006) Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapyNature Clinical Practice Oncology, 10.1038/ncponc0602, VOL. 3, NO. 10, (552-563), Online publication date: 1-Oct-2006. Shahinian V, Kuo Y, Freeman J and Goodwin J (2006) Determinants of Androgen Deprivation Therapy Use for Prostate Cancer: Role of the UrologistJNCI: Journal of the National Cancer Institute, 10.1093/jnci/djj230, VOL. 98, NO. 12, (839-845), Online publication date: 21-Jun-2006. Janowsky J (2006) The role of androgens in cognition and brain aging in menNeuroscience, 10.1016/j.neuroscience.2005.09.007, VOL. 138, NO. 3, (1015-1020), Online publication date: 1-Mar-2006. ISSA M, LENDVAY T, BOUET R, YOUNG M, PETROS J and MARSHALL F (2018) EPIDIDYMAL SPARING BILATERAL SIMPLE ORCHIECTOMY WITH EPIDIDYMOPLASTY: PRESERVATION OF ESTHETICS AND BODY IMAGEJournal of Urology, VOL. 174, NO. 3, (893-897), Online publication date: 1-Sep-2005. Shahinian V, Kuo Y, Freeman J, Orihuela E and Goodwin J (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinomaCancer, 10.1002/cncr.20955, VOL. 103, NO. 8, (1615-1624), Online publication date: 15-Apr-2005. Zeliadt S, Potosky A, Etzioni R, Ramsey S and Penson D (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999Urology, 10.1016/j.urology.2004.07.037, VOL. 64, NO. 6, (1171-1176), Online publication date: 1-Dec-2004. Trump D (2004) Androgen Deprivation for Men with PSA-Only Failure Following Radical Prostatectomy Management of Prostate Cancer, 10.1201/b14401-11, (307-338), Online publication date: 27-Oct-2004. ISSA M, KRISHNAN A, BOUET R, YOUNG M, HOOD N and PETROS J (2018) THE FATE OF THE MEDICALLY CASTRATED TESTIS: EXPECTATION VERSUS REALITYJournal of Urology, VOL. 172, NO. 3, (1042-1044), Online publication date: 1-Sep-2004. Sanguineti G, Marcenaro M, Franzone P, Tognoni P, Barra S and Vitale V (2004) Is There a "Curative" Role of Radiotherapy for Clinically Localized Hormone Refractory Prostate Cancer?American Journal of Clinical Oncology, 10.1097/01.coc.0000092565.46506.bc, VOL. 27, NO. 3, (264-268), Online publication date: 1-Jun-2004. Zietman A, Thakral H, Skowronski U and Shipley W (2002) Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/S0360-3016(02)02858-4, VOL. 53, NO. 5, (1152-1159), Online publication date: 1-Aug-2002. Dreicer R (2002) Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomyCancer Treatment Reviews, 10.1016/S0305-7372(02)00046-4, VOL. 28, NO. 4, (189-194), Online publication date: 1-Aug-2002. Fowler F, McNaughton Collins M, Walker Corkery E, Elliott D and Barry M (2002) The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinomaCancer, 10.1002/cncr.10656, VOL. 95, NO. 2, (287-295), Online publication date: 15-Jul-2002. BERRUTI A, DOGLIOTTI L, TERRONE C, CERUTTI S, ISAIA G, TARABUZZI R, REIMONDO G, MARI M, ARDISSONE P, DE LUCA S, FASOLIS G, FONTANA D, ROCCA ROSSETTI S and ANGELI A (2002) Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation TherapyThe Journal of Urology, 10.1097/00005392-200206000-00006, (2361-2367), Online publication date: 1-Jun-2002. BERRUTI A, DOGLIOTTI L, TERRONE C, CERUTTI S, ISAIA G, TARABUZZI R, REIMONDO G, MARI M, ARDISSONE P, DE LUCA S, FASOLIS G, FONTANA D, ROCCA ROSSETTI S and ANGELI A (2018) Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation TherapyJournal of Urology, VOL. 167, NO. 6, (2361-2367), Online publication date: 1-Jun-2002. Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa R, Angeli A and Dogliotti L (2002) Background to and Management of Treatment-Related Bone Loss in Prostate CancerDrugs & Aging, 10.2165/00002512-200219120-00002, VOL. 19, NO. 12, (899-910), . Hayat M (2002) 1 Prostate carcinoma: An introduction Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma, 10.1016/S1874-5784(02)80033-2, (279-297), . Iversen P (2001) EDITORIAL: QUALITY OF LIFE ISSUES FOR PATIENTS WITH PROSTATE CANCERThe Journal of Urology, 10.1097/00005392-200112000-00059, (2291-2292), Online publication date: 1-Dec-2001. Bubolz T, Wasson J, Lu-Yao G and Barry M (2001) Treatments for prostate cancer in older men: 1984–1997Urology, 10.1016/S0090-4295(01)01434-0, VOL. 58, NO. 6, (977-982), Online publication date: 1-Dec-2001. Iversen P (2018) EDITORIAL: QUALITY OF LIFE ISSUES FOR PATIENTS WITH PROSTATE CANCERJournal of Urology, VOL. 166, NO. 6, (2291-2292), Online publication date: 1-Dec-2001. Lubeck D, Grossfeld G and Carroll P (2001) The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancerUrology, 10.1016/S0090-4295(01)01250-X, VOL. 58, NO. 2, (94-99), Online publication date: 1-Aug-2001. MARIANI A, GLOVER M and ARITA S (2018) MEDICAL VERSUS SURGICAL ANDROGEN SUPRESSION THERAPY FOR PROSTATE CANCER: A 10-YEAR LONGITUDINAL COST STUDYJournal of Urology, VOL. 165, NO. 1, (104-107), Online publication date: 1-Jan-2001. HERR H and O???SULLIVAN M (2000) QUALITY OF LIFE OF ASYMPTOMATIC MEN WITH NONMETASTATIC PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPYThe Journal of Urology, 10.1097/00005392-200006000-00025, (1743-1746), Online publication date: 1-Jun-2000. HERR H and O'SULLIVAN M (2018) QUALITY OF LIFE OF ASYMPTOMATIC MEN WITH NONMETASTATIC PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPYJournal of Urology, VOL. 163, NO. 6, (1743-1746), Online publication date: 1-Jun-2000. Wei J, Gross M, Jaffe C, Gravlin K, Lahaie M, Faerber G and Cooney K (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone densityUrology, 10.1016/S0090-4295(99)00301-5, VOL. 54, NO. 4, (607-611), Online publication date: 1-Oct-1999. Parker C and Dearnaley D (1998) The management of PSA failure after radical radiotherapy for localized prostate cancerRadiotherapy and Oncology, 10.1016/S0167-8140(98)00107-8, VOL. 49, NO. 2, (103-110), Online publication date: 1-Nov-1998. Volume 159Issue 6June 1998Page: 1993-1997 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.Metrics Author Information JOHN H. WASSON More articles by this author FLOYD J. FOWLER More articles by this author MICHAEL J. BARRY More articles by this author Expand All Advertisement PDF downloadLoading ...